Maximilian Mair, MD PhD, is working as a postdoctoral researcher and resident in Medical Oncology at the Medical University of Vienna, Austria. His research focuses on systemic treatment of primary brain tumors, with a main interest on gliomas and meningiomas. Currently, he is pursuing a postdoctoral fellowship at LMU Hospital in Munich (Germany), where his work centers on diagnostic and therapeutic applications of nuclear medicine in CNS malignancies.

George Petrescu, MD, PhD, is a neurosurgeon and lecturer at Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. His research interests include finding new therapeutic targets for primary brain tumors and improving the quality of life of neuro-oncological patients following surgical resection. He is also involved in developing educational applications using modern techniques such as extended reality for teaching medical students and residents interested in the field of neuro-oncology, as well as for informing patients.

Franziska Maria Ippen, MD, is currently a neurology resident at the University Hospital Heidelberg, Germany, and a fellow of the National Center of Tumor Diseases (NCT) Heidelberg School of Oncology, a joint program with the German Cancer Research Center (DKFZ) Heidelberg. Her research focuses on targeted therapies in the field of neuro-oncology, brain metastases and leptomeningeal disease.

Felix Ehret, MD, is a radiation oncology resident and assistant professor in the Department of Radiation Oncology at Charité, Berlin, Germany. He is also a current research fellow at Massachusetts General Hospital and Harvard Medical School. His research interests focus on refining radiotherapy for meningiomas and gliomas. Additionally, he investigates the use of stereotactic radiosurgery and stereotactic body radiotherapy, encompassing both clinical and translational projects.

Antonio C. Fuentes-Fayos, PhD, is a postdoctoral researcher at the Regenerative Medicine Institute at Cedars-Sinai Medical Center, Los Angeles. His research focuses on the immunopeptidome of brain tumors, utilizing cutting-edge molecular analyses, single-cell sequencing, peptidomics, and advanced modeling techniques. Through this work, he aims to characterize the diverse cell populations within gliomas and explore the complex interactions between the immune response, tumor evolution, and the efficacy of existing therapies.

Maximilian Mastall, MD, PhD, is a neurology resident at the University Hospital Zurich, Switzerland. He obtained his MD focusing on immune cell infiltration into glioblastoma at the Neurosurgical Department of the University Hospital Heidelberg, Germany. Recently, he completed his PhD in Cancer Biology, generating Chimeric Antigen Receptor (CAR) T cells against glioblastoma. His research interests are novel immunotherapeutic strategies for patients with malignant brain tumors.